# A Clinical Study Evaluating the Efficacy and Safety of CMS-D001 Tablets in the Treatment of Adult Patients With Moderate to Severe Plaque-type Psoriasis

> **NCT07432854** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Dermavon Holdings Limited** · enrollment: 540 (estimated)

## Conditions studied

- Moderate to Severe Plaque Psoriasis

## Interventions

- **DRUG:** CMS-D001 50mg
- **DRUG:** CMS-D001 100mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07432854
- **Lead sponsor:** Dermavon Holdings Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-03
- **Primary completion:** 2028-02-29
- **Final completion:** 2028-07-30
- **Target enrollment:** 540 (ESTIMATED)
- **Last updated:** 2026-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07432854

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07432854, "A Clinical Study Evaluating the Efficacy and Safety of CMS-D001 Tablets in the Treatment of Adult Patients With Moderate to Severe Plaque-type Psoriasis". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT07432854. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*